New triple therapy shows promise in stomach cancer fight
NCT ID NCT04208347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy and the targeted drug apatinib improves outcomes for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 580 adults will receive the treatment before and after surgery. The goal is to see if this combination leads to more complete tumor disappearance and longer survival without the cancer coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Hebei University
Baoding, China
-
Affiliated Hospital of Jiangsu University
Zhenjiang, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
-
Cancer Hospital of the University of Chinese Academy of Sciences
Hangzhou, China
-
Changhai Hospital
Shanghai, China
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
Hainan Cancer Hospital
Haikou, China
-
Hefei Cancer Hospital, Chinese Academy of Sciences
Hefei, China
-
Henan Provincial Cancer Hospital
Zhengzhou, China
-
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, China
-
Jilin Guowen Hospital
Siping, China
-
Lanzhou University Second Hospital
Lanzhou, China
-
Liaoning Cancer Hospita & Institute
Shenyang, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, China
-
Sichuan Cancer Hospital & Institute
Chengdu, China
-
Sichuan Provincial People's Hospital
Chengdu, China
-
Tangdu Hospital
Xi'an, China
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
-
Xiangya Hospital Central South University
Changsha, China
-
Yantai Yuhuangding Hospital
Yantai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can stomach cancer surgery also tame diabetes?
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?